Semperis Announces $40 Million in Growth Funding After Completing Six Consecutive Profitable Quarters
Semperis, the pioneer of identity-driven cyber resilience for enterprises, today announced $40 million in Series B funding. Global venture capital and private equity firm Insight Partners led the round with participation from existing investors. The new investment follows Semperis completing its sixth consecutive profitable quarter, bringing total funding to $54 million. With this capital infusion, Semperis will continue to expand its global presence and accelerate hiring across all functional areas.
Semperis also announced that Teddie Wardi, Managing Director at Insight Partners, and Charlie Federman, Partner at SilverTech Ventures, will be joining its board of directors.
“Across every industry, companies are waking up to the fact that ransomware can literally shut off the lights and end their business if recovery isn’t swift and secure,” said Wardi. “With ransomware damages projected to reach $20 billion by 2021, Semperis is filling an enormous gap, especially for organizations that can’t tolerate lengthy outages or degraded service. We’re thrilled to partner with the team and help them scale.”
Semperis partners with government agencies and Global 2000 enterprises to empower comprehensive protection for their directory services on-premises and in the cloud. With Semperis, organizations can continuously monitor their directories for security vulnerabilities, intercept cyber-attacks in progress, and quickly respond to breaches and operational errors.
“This funding event marks a significant milestone for Semperis, and we’re proud to have such an elite group of investors joining us in our mission,” said Mickey Bresman, CEO, Semperis. “Cybersecurity programs, big and small, are on the front lines of a new war that has virtually no boundaries and no rules of engagement. If you think about hospitals that can’t access their systems to save a life, or cities that get held hostage, we have a responsibility to help organizations take back control. That’s what drives us.”
As the gatekeeper to critical applications and data, Microsoft Active Directory (AD) has become a prime target for widespread attacks that have crippled businesses in recent years. The most destructive attack to date, NotPetya, wrought $10 billion in total damages in 2017 according to White House officials. Like many high-profile companies impacted by NotPetya, the world’s largest shipping firm, Maersk, spent over a week manually recovering its Active Directory.
“NotPetya ushered in an entirely new era of cyberwarfare and AD is in its crosshairs,” Bresman added. As reported, Maersk emphasized that nine days for an AD recovery isn't good enough. Because if you can’t recover AD, then you can't repair anything else and business halts. Organizations must be able to safely automate AD recovery even if host servers are infected or wiped out.”
In 2019, Semperis introduced a cyber-first approach to disaster recovery for Active Directory. The company's patented technology fully automates the Active Directory recovery process, avoids human errors, reduces downtime to minutes instead of days or even weeks, and eliminates the risk of malware reinfection.
“Semperis is a mission-driven company uniquely positioned to not only help organizations prevent costly downtime, but also to curb the funding of evil,” said Edward Amoroso, founder and CEO, TAG Cyber. While COVID-19 is disrupting many aspects of daily living, it’s not slowing down the work of nation-state hackers and cybercriminals. When organizations can say ‘no’ to blackmail and ransom demands, we’re all safer.”
Headquartered in New York City, Semperis’ team of identity experts and Microsoft MVPs bring vast experience building and operating world-class cybersecurity programs. For more information, visit www.semperis.com or follow Semperis on Twitter @SemperisTech.
Semperis is the pioneer of identity-driven cyber resilience for cross-cloud and hybrid environments. The company provides cyber preparedness, incident response, and disaster recovery solutions for enterprise directory services—the keys to the kingdom. Semperis’ patented technology for Microsoft Active Directory protects over 40 million identities from cyberattacks, data breaches, and operational errors. Semperis is headquartered in New York City and operates internationally, with its research and development team distributed between San Francisco and Tel Aviv.
Semperis hosts the award-winning Hybrid Identity Protection conference. The company has received the highest level of industry accolades; most recently being named Best Business Continuity / Disaster Recovery Solution by SC Magazine’s 2020 Trust Awards. Semperis is accredited by Microsoft and recognized by Gartner.
About Insight Partners
Insight Partners is a leading global venture capital and private equity firm investing in high-growth technology and software ScaleUp companies that are driving transformative change in their industries. Founded in 1995, Insight Partners has invested in more than 400 companies worldwide and has raised through a series of funds more than $30 billion in capital commitments. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with practical, hands-on software expertise to foster long-term success. Across its people and its portfolio, Insight encourages a culture around a belief that ScaleUp companies and growth create opportunity for all. For more information on Insight and all its investments, visit www.insightpartners.com or follow us on Twitter @insightpartners.
Madison Alexander PR
For Insight Partners:
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25th European Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leuke
Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo
LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 14:57:00 EEST | Press release
LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing
Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis129.5.2020 14:38:00 EEST | Press release
Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases with a progressive phenotype beyond IPF.1 The opinion is based on the positive results of the INBUILD® phase III trial, the first study to evaluate adults with a broad range of chronic fibrosing interstitial lung diseases (ILDs) and a progressive disease behaviour.2 This follows the FDA’s and Health Canada’s approval of nintedanib as the first treatment for the same patient population.3,4 Interstitial lung diseases encompass a large group of more than 200 disorders that may involve the threat of pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function.5 People living with fibrosing ILD can develop a progressive phenotype, leading to lung functio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom